These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 2515715)

  • 1. Selegiline in the treatment of Parkinson's disease.
    Heinonen EH; Rinne UK
    Acta Neurol Scand Suppl; 1989; 126():103-11. PubMed ID: 2515715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of a dopamine agonist, MAO-B inhibitor and levodopa--a new strategy in the treatment of early Parkinson's disease.
    Rinne UK
    Acta Neurol Scand Suppl; 1989; 126():165-9. PubMed ID: 2515722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deprenyl (selegiline) in the treatment of Parkinson's disease.
    Birkmayer W
    Acta Neurol Scand Suppl; 1983; 95():103-5. PubMed ID: 6428140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selegiline in the treatment of daily fluctuations in disability of parkinsonian patients with long-term levodopa treatment.
    Heinonen EH; Rinne UK; Tuominen J
    Acta Neurol Scand Suppl; 1989; 126():113-8. PubMed ID: 2515716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type B monoamine oxidase inhibitor in 200 patients.
    Elizan TS; Yahr MD; Moros DA; Mendoza MR; Pang S; Bodian CA
    Arch Neurol; 1989 Dec; 46(12):1280-3. PubMed ID: 2511825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deprenyl (selegiline) in combination treatment of Parkinson's disease.
    Gerstenbrand F; Ransmayr G; Poewe W
    Acta Neurol Scand Suppl; 1983; 95():123-6. PubMed ID: 6428144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.
    Heinonen EH; Myllylä V
    Drug Saf; 1998 Jul; 19(1):11-22. PubMed ID: 9673855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. R-(-)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson's disease.
    Rinne UK
    J Neural Transm Suppl; 1987; 25():149-55. PubMed ID: 3123601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of the pharmacology of selegiline.
    Heinonen EH; Lammintausta R
    Acta Neurol Scand Suppl; 1991; 136():44-59. PubMed ID: 1686954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deprenyl (selegiline) in the treatment of Parkinson's disease.
    Rinne UK
    Acta Neurol Scand Suppl; 1983; 95():107-11. PubMed ID: 6428141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selegiline--an overview of its role in the treatment of Parkinson's disease.
    Wessel K; Szelenyi I
    Clin Investig; 1992 May; 70(5):459-62. PubMed ID: 1600360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa.
    Schachter M; Marsden CD; Parkes JD; Jenner P; Testa B
    J Neurol Neurosurg Psychiatry; 1980 Nov; 43(11):1016-21. PubMed ID: 6777463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (-)Deprenyl in the treatment of Parkinson's disease.
    Birkmayer W; Riederer P; Youdim MB
    Clin Neuropharmacol; 1982; 5(2):195-230. PubMed ID: 6814755
    [No Abstract]   [Full Text] [Related]  

  • 14. New approaches in the use of selegiline for the treatment of Parkinson's disease.
    Lees AJ; Frankel J; Eatough V; Stern GM
    Acta Neurol Scand Suppl; 1989; 126():139-45. PubMed ID: 2515719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selegiline in the early and late phases of Parkinson's disease.
    Csanda E; Tárczy M
    J Neural Transm Suppl; 1987; 25():105-13. PubMed ID: 3123597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New strategies in the treatment of early Parkinson's disease.
    Rinne UK
    Acta Neurol Scand Suppl; 1991; 136():95-8. PubMed ID: 1801545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of selegiline and controlled release levodopa in the treatment of fluctuations of clinical disability in parkinsonian patients.
    Chouza C; Aljanati R; Scaramelli A; De Medina O; Caamaño JL; Buzo R; Fernandez A; Romero S
    Acta Neurol Scand Suppl; 1989; 126():127-37. PubMed ID: 2515718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selegiline and levodopa in early or moderately advanced Parkinson's disease: a double-blind controlled short- and long-term study.
    Sivertsen B; Dupont E; Mikkelsen B; Mogensen P; Rasmussen C; Boesen F; Heinonen E
    Acta Neurol Scand Suppl; 1989; 126():147-52. PubMed ID: 2515720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selegiline use to prevent progression of Parkinson's disease. Experience in 22 de novo patients.
    Elizan TS; Yahr MD; Moros DA; Mendoza MR; Pang S; Bodian CA
    Arch Neurol; 1989 Dec; 46(12):1275-9. PubMed ID: 2511824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selegiline for Parkinson's disease.
    Calesnick B
    Am Fam Physician; 1990 Feb; 41(2):589-91. PubMed ID: 2105624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.